Top Page
OncoSil Medical Ltd
(Sydney:OSL)
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
OncoSil Medical Ltd Business Overview & Revenue Model
OncoSil Medical Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -4.06M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.08M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -15.10M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.15M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.11M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 69.92K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 4.04M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.10M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.08M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.06M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -14.96K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 12.73M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$73.46M | ― | -128.19% | ― | -14.25% | -22.83% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$897.90M | ― | -44.49% | ― | 55.91% | 22.60% | |
| ― | AU$28.99M | -1.11 | -385.20% | ― | 126.62% | 33.53% | |
| ― | AU$170.03M | -16.13 | -70.55% | ― | ― | -257.32% | |
| ― | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% | |
| ― | AU$14.14M | ― | -103.74% | ― | 14.84% | 39.64% |
OncoSil Medical Ltd Corporate Events
OncoSil Medical Ltd announced the cessation of 18,942 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects on the company’s operational challenges in meeting set conditions for securities.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced its Annual General Meeting (AGM) scheduled for November 19, 2025, at K&L Gates in Melbourne. Shareholders are invited to participate in the meeting, with options to vote online or by proxy if unable to attend. This meeting is a significant event for stakeholders, providing an opportunity to discuss the company’s progress and future strategies.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd recently addressed a query from the ASX regarding the disclosure of results from the PANCOSIL trial, a Phase 1-2 feasibility study conducted by Amsterdam University Medical Centre. The trial, which investigates the safety and feasibility of CT-guided percutaneous placement of the OncoSil™ device, showed promising preliminary results, including a 90% feasibility rate for tumor ablation. The company promptly implemented a trading halt to analyze the results and released an announcement to the ASX, highlighting the potential impact of these findings on their operations and market positioning.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has released a presentation to provide an overview of its operations and future prospects. The company is focused on the development of medical devices for cancer treatment, specifically targeting pancreatic cancer. The presentation includes forward-looking statements about potential regulatory approvals and commercial success, although it cautions that actual results may differ due to various risks and uncertainties. Stakeholders are advised to consider these factors and seek independent advice when evaluating the company’s future performance.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced positive preliminary results from its PANCOSIL Phase 1-2 study, which demonstrates the safety and feasibility of delivering the OncoSil™ device via CT-guided percutaneous administration for treating locally advanced pancreatic cancer. The study showed a 90% technical success rate and a median overall survival of 20.6 months, surpassing the typical 13 months for LAPC. These findings could lead to further regulatory approvals and expand the use of OncoSil™ therapy, potentially transforming treatment delivery and increasing adoption in clinical practice.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has announced an investor webinar scheduled for 18 September 2025, where CEO Nigel Lange will discuss preliminary results from the PANCOSIL Investigator Initiated Study. This event highlights OncoSil’s ongoing efforts to engage with stakeholders and provide updates on their innovative cancer treatment solutions, potentially impacting their market positioning and stakeholder relations.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has announced that its Annual General Meeting will be held on November 19, 2025, in Melbourne, with the deadline for director nominations set for October 1, 2025. This announcement is significant for stakeholders as it outlines the company’s governance timeline and provides an opportunity for shareholder engagement. Further details about the AGM will be shared in the Notice of Meeting, highlighting the company’s commitment to transparency and shareholder communication.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd announced the issuance of 2,322 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, confirming compliance with relevant legal provisions and the absence of excluded information. This move reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the medical device sector, particularly in expanding the reach and application of its OncoSil™ device for pancreatic cancer treatment.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced the quotation of 2,322 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing operations, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has announced the appointment of Dr. Thomas Duthy as the new Non-Executive Chairman, effective 1 October 2025. Dr. Duthy, who brings over 20 years of experience in healthcare and technology, replaces Mr. Doug Cubbin, who will transition to a Non-Executive Director role. This strategic change is expected to support OncoSil’s growth in existing and new markets, as well as enhance clinical data generation to boost clinician adoption and market access. The announcement reflects OncoSil’s ongoing commitment to advancing its OncoSil™ device and achieving key milestones for its availability in targeted regions.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd announced that the preliminary results of its PANCOSIL Phase 1-2 trial will be presented at the CIRSE Annual Congress in September 2025. The trial, conducted by Amsterdam University Medical Center, evaluates the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer. The study aims to simplify the administration of the OncoSil™ device, potentially enhancing market penetration and clinical use. The announcement aligns with OncoSil’s expectations for releasing initial trial results in the September 2025 quarter.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has announced a change in its registered office address to Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113, Australia. This change is part of the company’s compliance with ASX Listing Rule 3.14. The move is a procedural update and does not indicate any strategic shift or operational impact on the company’s focus or market positioning.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has announced the joint appointment of Mr. Tim Luscombe and Mr. David Wood as Joint Company Secretaries, effective September 1, 2025. This change follows the resignation of Ms. Olga Smejkalova. The new appointees are part of Bio101 Financial Advisory, bringing expertise in financial management and corporate governance to the company. This strategic move is expected to enhance OncoSil’s operational efficiency and strengthen its governance framework, potentially impacting its industry positioning positively.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, confirming compliance with key recommendations and detailing governance practices. This announcement underscores OncoSil’s commitment to transparency and regulatory compliance, potentially strengthening stakeholder confidence and supporting its market position.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd reported a significant increase in revenue by 126.6% to $1,170,793 for the year ending June 30, 2025, despite a 26.7% rise in losses to $15,099,844. The company did not declare any dividends during this period. A notable decrease in net tangible assets per ordinary security was observed, dropping from 57.32 cents to 21.86 cents. The upcoming Annual General Meeting is scheduled for November 19, 2025, where key decisions regarding the company’s future direction will be discussed. The financial statements have been audited, with an unmodified opinion issued, although a material uncertainty related to going concern was noted.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Ltd has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). The company is set to quote 41,667 options expiring on July 31, 2027, as part of its strategic financial maneuvers. This move is likely to impact the company’s financial positioning and provide additional resources to support its ongoing projects and market expansion efforts.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
OncoSil Medical Limited has released an investor webinar presentation highlighting its recent achievements and future commercial milestones. The company reported record sales of its OncoSil™ device in the fourth quarter of FY25 and is expanding its geographic footprint, including targeting the US market. The presentation also covered upcoming clinical studies in Germany and detailed the allocation of funds from a recent capital raise, indicating strategic growth and enhanced market positioning.
OncoSil Medical Limited announced an investor webinar to discuss its recent achievements and future milestones, including record sales of its OncoSil™ device and plans to expand its geographic footprint, particularly targeting the US market. The webinar will also cover the company’s ongoing studies demonstrating the device’s superior outcomes, a new clinical study in Germany, and the allocation of funds from a recent capital raise. This announcement highlights OncoSil’s strategic efforts to strengthen its market position and enhance its operational capabilities, potentially benefiting stakeholders through expanded market reach and improved treatment outcomes.
OncoSil Medical Ltd reported a strong quarter with record dose sales in Q4 FY25, driven by increased clinical adoption and demand from treatment centers. The company achieved a 20% increase in dose sales compared to the previous quarter and a 42% increase for the full fiscal year, leading to a 66% rise in annual revenue. Additionally, OncoSil Medical completed a successful $8.7 million capital raise to support commercialization efforts and signed a distribution agreement for Slovenia. The company also announced a significant clinical study in Germany, which could enhance its market positioning by generating evidence for national reimbursement. Furthermore, a comparative study presented at Digestive Disease Week 2025 demonstrated superior outcomes for patients treated with OncoSil™ compared to Stereotactic Body Radiation Therapy, highlighting its potential as a valuable treatment option.